NL-OMON46354
Recruiting
Not Applicable
A single arm multicenter biomarker study determining the response to taxane-based chemotherapy in metastatic breast cancer (MBC) patients with ESR1 mutations in cell-free DNA: TAX-ESR1 study. - TAX-ESR1 study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Metastasis of breast cancer
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 175
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Female metastatic breast cancer patients with ER\-positive, HER2\- negative primary tumors;
- •2\. Previous treatment with at least an aromatase inhibitor either in adjuvant and/or metastatic setting;
- •3\. Failure to previous treatment with at least one type of aromatase inhibitor (non\-steroidal/steroidal) for MBC;
- •4\. Considered fit enough to receive taxane\-based chemotherapy by the treating physician; either as a first line chemotherapy for metastatic breast cancer or as second line treatment if the time between completion of first line chemotherapy for metastatic breast cancer and inclusion is more than three years.
- •5\. Intention to start with either paclitaxel and docetaxel;
- •6\. Patient with measurable or clinically evaluable (bone only) disease on recent standard work\-up for MBC;
- •7\. CT chest and abdomen must not be older than 42 days on the day of the anticipated treatment start;
- •8\. Age \>\=18 years old;
- •9\. WHO performance status 0\-2;
- •10\. Signed written informed consent;
Exclusion Criteria
- •1\. Previous chemotherapy for metastatic disease, completed within three years before inclusion;
- •2\. Patients with locally advanced disease, primary not amendable for resection or radiation therapy with curative intent;
- •3\. (neo)adjuvant chemotherapy within 6 months prior to treatment start;
- •4\. Anti\-hormonal treatment for breast cancer within two weeks prior to treatment start;
- •5\. Symptomatic CNS metastasis (the presence of at least one key symptom in combination with radiologic evidence (positive contrast\-enhanced CT or MRI of the brain)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A single arm multicenter biomarker study determining the response to taxane-based chemotherapy in metastatic breast cancer patients with ESR1 mutations in cellfree DNAbreast cancer, metastasis, ESR1 mutations, chemotherapyNL-OMON25511Erasmus MC Cancer Institute, department of Medical Oncology185
Recruiting
Not Applicable
A multicenter study for validation of biomarkers and observational study for immune regulatory mechanisms in Juvenile Dermatomyositisjuvenile dermatomyositisrheumatic muscle disease1000381610028302NL-OMON50706niversitair Medisch Centrum Utrecht365
Completed
Not Applicable
A Multicenter Study on Biomarker Development Utilizing AI Multiomics for Patients with Advanced Solid Malignant TumorsAdvanced Solid MalignanciesJPRN-UMIN000043899ational Cancer Center Hospital East2,768
Active, not recruiting
Phase 1
A study to treat adult patients with a medicine who suffer from a low amount of remaining blood cancer cells after chemotherapy.minimal residual disease (MRD) of B-precursor ALLMedDRA version: 14.1 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemia System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-018314-75-PLAmgen Research (Munich) GmbH130
Active, not recruiting
Phase 1
A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia - MT103-203minimal residual disease (MRD) of B-precursor ALLMedDRA version: 12.1 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemiaEUCTR2010-018314-75-FRMicromet AG130